Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NVO

Novo Nordisk ADR

Dec 19 • 04:00PM ET

48.09

+0.48 1.01 %

Healthcare • Drug Manufacturers - General • Denmark • NYSE

Peers: LLY MRK ABBV JNJ AMGN AZN PFE SNY BMY GSK

| Held by: PVAL PPH AVDE FTHI RVER WCMI PID AQEC APIE QLTI

Scroll to Statements

Index	-	P/E	14.01	EPS (ttm)	3.43	Insider Own	0.00%	Shs Outstand	3.37B	Perf Week	-4.17%
Market Cap	162.00B	Forward P/E	13.68	EPS next Y	3.52	Insider Trans	-	Shs Float	3.37B	Perf Month	-1.86%
Enterprise Value	172.80B	PEG	2.49	EPS next Q	0.92	Inst Own	9.03%	Short Float	0.88%	Perf Quarter	-20.79%
Income	15.29B	P/S	3.47	EPS this Y	15.66%	Inst Trans	-1.44%	Short Ratio	1.82	Perf Half Y	-31.02%
Sales	46.69B	P/B	7.99	EPS next Y	-3.83%	ROA	21.83%	Short Interest	29.59M	Perf YTD	-44.09%
Book/sh	6.02	P/C	31.58	EPS next 5Y	5.49%	ROE	68.30%	52W High	104.75 -54.09%	Perf Year	-55.48%
Cash/sh	1.52	P/FCF	16.20	EPS past 3/5Y	25.78% 21.74%	ROIC	37.50%	52W Low	43.08 11.63%	Perf 3Y	-28.61%
Dividend Est.	1.77 (3.68%)	EV/EBITDA	7.50	Sales past 3/5Y	23.46% 18.15%	Gross Margin	81.93%	Volatility	2.20% 2.51%	Perf 5Y	39.96%
Dividend TTM	1.73 (3.59%)	EV/Sales	3.70	EPS Y/Y TTM	11.24%	Oper. Margin	42.41%	ATR (14)	1.47	Perf 10Y	73.17%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	0.57	Sales Y/Y TTM	18.71%	Profit Margin	32.76%	RSI (14)	46.95	Recom	2.27
Dividend Gr. 3/5Y	28.20% 21.81%	Current Ratio	0.78	EPS Q/Q	-21.84%	SMA20	-0.07%	Beta	0.67	Target Price	60.01
Payout	35.93%	Debt/Eq	0.60	Sales Q/Q	11.80%	SMA50	-3.82%	Rel Volume	0.65	Prev Close	47.61
Employees	76302	LT Debt/Eq	0.52	Earnings	Nov 05 BMO	SMA200	-21.00%	Avg Volume	16.27M	Price	48.09
IPO	Apr 30, 1981	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.41% -3.47%	Trades		Volume	10,610,367	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-08-25	Downgrade	Argus	Buy → Hold
Oct-27-25	Resumed	Jefferies	Underperform
Oct-01-25	Upgrade	HSBC Securities	Hold → Buy
Sep-29-25	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$47
Sep-17-25	Upgrade	Berenberg	Hold → Buy
Sep-16-25	Upgrade	Rothschild & Co Redburn	Neutral → Buy
Sep-09-25	Upgrade	Bernstein	Mkt Perform → Outperform
Aug-13-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$54
Aug-05-25	Downgrade	UBS	Buy → Neutral
Jul-31-25	Downgrade	HSBC Securities	Buy → Hold	$57
Jul-30-25	Downgrade	Barclays	Overweight → Equal Weight
Apr-17-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$64
Mar-13-25	Upgrade	Kepler	Hold → Buy
Mar-03-25	Downgrade	Stifel	Buy → Hold
Feb-12-25	Initiated	Morgan Stanley	Equal-Weight
Jan-06-25	Upgrade	Bernstein	Underperform → Mkt Perform
May-30-24	Initiated	Goldman	Buy	$156
Apr-12-24	Initiated	BMO Capital Markets	Outperform	$163
Jan-23-24	Initiated	Morgan Stanley	Overweight	$120
Jan-16-24	Resumed	UBS	Neutral

Show Previous Ratings

Dec-19-25 09:31PM	After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss (Benzinga)
05:40PM	Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump (Investor's Business Daily)
04:07PM	Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap. (Barrons.com)
02:53PM	?Novo Nordisk (NVO) Receives Positive Opinion For Wegovy By European Medicines Agency (Insider Monkey)
10:52AM	Did Eli Lilly Just Find the Holy Grail of Weight Loss? (24/7 Wall St.)
08:59AM	Loading…
08:59AM	Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema (Zacks)
06:40AM	Eli Lillys oral GLP-1RA maintains weight loss from injectable drugs (Clinical Trials Arena)
06:01AM	Novo files for CagriSema approval; Merck and Pfizers trial win (BioPharma Dive)
Dec-18-25 09:20PM	Prediction: 1 Healthcare Giant Set to Soar in 2026 (Motley Fool)
05:14PM	Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound (CNBC TV)
04:36PM	Eli Lilly, IBD Stock Of The Day, Proves The Merit Of Its Weight-Loss Pill (Investor's Business Daily)
03:57PM	Obesity pill race heats up (CNBC TV)
01:55PM	Eli Lilly Obesity Pill Maintains Weight Loss After Wegovy, Zepbound (GuruFocus.com)
01:09PM	Lilly says obesity pill can replace shot after weight loss (Quartz)
11:54AM	Lose Weight on Zepbound, Keep It Off With Eli Lillys New Pill? Data Say That Works. (Barrons.com)
09:53AM	Loading…
09:53AM	Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share? (Zacks)
09:49AM	Eli Lilly's Weight-Loss Pill Succeeds In A First-Of-Its-Kind Study (Investor's Business Daily)
09:28AM	A new generation of weight-loss drugs is getting closer to patients. Here's how they differ from Wegovy and Zepbound. (MarketWatch)
09:20AM	Novo Nordisk (NVO) Fell Following a Profit Warning Release (Insider Monkey)
09:09AM	Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema (The Wall Street Journal)
07:05AM	Better Buy in 2026: Novo Nordisk or Intuitive Surgical? (Motley Fool)
04:10AM	Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk (Motley Fool)
Dec-17-25 05:45PM	Why Novo Nordisk (NVO) Dipped More Than Broader Market Today (Zacks)
05:12PM	UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress (Insider Monkey)
09:59AM	Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? (Zacks)
08:57AM	Novo Nordisk (NVO) Hit By Lowered Guidance (Insider Monkey)
Dec-16-25 04:59PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:19PM	Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' (Investor's Business Daily)
09:44AM	Eli Lilly or Merck: Where Should Investors Put Their Money? (Zacks)
07:03AM	Pfizer Adds to Its Big Bet on Weight Loss Drugs (MarketBeat)
10:32AM	Loading…
Dec-15-25 10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
09:00AM	Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know (Zacks)
04:30AM	Eli Lilly Just Delivered Fantastic News to Investors (Motley Fool)
Dec-14-25 09:50AM	2 Predictions for Novo Nordisk in 2026 (Motley Fool)
Dec-13-25 04:30AM	My Top 10 Stocks to Buy for 2026 (Motley Fool)
Dec-12-25 04:04PM	Eli Lilly Rises, Again, After EMA Groups Recommends Mounjaro For Children As Young As 10 (Investor's Business Daily)
01:52PM	Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound (GuruFocus.com)
11:31AM	Novo Nordisk Is Selling Ozempic for $24 a Week in India. Why Its So Cheap. (Barrons.com)
11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
09:04AM	Ozempic Has a $24 a Week Price Tag in India. Why Novo Nordisks Selling at Such a Discount to the U.S. (Barrons.com)
09:00AM	Ozempic launches in India at $24 a week as Novo targets booming market (Reuters Videos)
08:18AM	Novo Nordisk Stumbles as Obesity Drug Race Heats Up (GuruFocus.com)
07:41AM	Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut. (Barrons.com)
07:31AM	Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts (Insider Monkey)
06:33AM	Novo Nordisk Launches Ozempic in India at $24 a Week (GuruFocus.com)
12:01AM	Oh no, Ozempic! Eli Lillys New Weight-Loss Drug KOs Rival Treatments (The Daily Upside)
Dec-11-25 08:14PM	Why Novo Nordisk Stock Topped the Market on Thursday (Motley Fool)
05:45PM	Novo Nordisk (NVO) Laps the Stock Market: Here's Why (Zacks)
04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
02:00PM	Stocks to Watch Thursday: Disney, Eli Lilly, Coca-Cola, Rivian (The Wall Street Journal)
10:23AM	Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge? (Zacks)
10:15AM	WVE Stock Surges More Than 180% in a Week: What Is Driving This Rally? (Zacks)
09:30AM	Eli Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial (The Wall Street Journal)
09:12AM	GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell? (Zacks)
08:33AM	Lilly Reports Positive Results in Next-Gen Obesity Drug Trial (The Wall Street Journal)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
07:32AM	Novo Nordisk (NVO) Partners With Indian Health-Tech Startup (Insider Monkey)
01:15AM	Novo Nordisk Is Trading as If Obesity Drug Craze Never Happened (Bloomberg)
Dec-10-25 05:27PM	Golden Cross Alert: 3 Stocks With Major Upside Potential (MarketBeat) +5.80%
04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:35PM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
04:15PM	Hims stock falls after lawmakers propose GLP-1 compounding restrictions (Investing.com)
12:42PM	3 Absurdly Cheap Stocks That Look Like Steals Right Now (Motley Fool)
11:28AM	Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy (Insider Monkey)
10:33AM	Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends (Insider Monkey)
10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
06:26AM	The Fed's Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today. (Barrons.com)
04:30AM	China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer (South China Morning Post)
Dec-09-25 04:13PM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
12:30PM	Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill (GuruFocus.com)
11:12AM	Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play (Zacks)
09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
05:59AM	Pfizer dips into China for another try at an obesity pill (BioPharma Dive)
Dec-08-25 03:36PM	Why Novo Nordisk Stock Was Melting on Monday (Motley Fool)
12:46PM	Obesity Biotechs Gains Hit Shares of Eli Lilly, Novo Nordisk (Barrons.com)
10:36AM	Structure Therapeutics Stock Jumps on Trial Results for Weight-Loss Pill (The Wall Street Journal)
Dec-05-25 04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:25PM	Do These 3 Healthcare Stocks Need a Checkup? (Motley Fool)
11:25AM	This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? (Motley Fool)
07:59AM	Wegovy's prices are going down, but they are 'wildly different' (MarketWatch)
Dec-04-25 01:50PM	Denmark's $600 Billion Economy Just Got a Boost--Thanks to One Drugmaker (GuruFocus.com)
01:48PM	Novo Nordisk Stock Rises -- Alzheimer's Program Hints at Potential Gains (GuruFocus.com)
11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
11:06AM	Hims & Hers Stock Gains on Move Into Canada (The Wall Street Journal)
10:29AM	Novo Nordisk A/S (NVO): A Bull Case Theory (Insider Monkey)
10:15AM	The Three Moves Hims & Hers Made This Week To Bolster Its Weight-Loss Biz (Investor's Business Daily)
08:42AM	Novo Nordisk Leans on India After Trial Miss (GuruFocus.com)
05:41AM	Novo Nordisk gears up for Ozempic launch in India, sources say (Reuters Videos)
Dec-03-25 01:10PM	1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year (Motley Fool)
09:30AM	Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? (Motley Fool)
09:26AM	Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? (Zacks)
Dec-02-25 12:28PM	LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website (Zacks)
11:23AM	Novo's $1 Billion Obesity Bet Just Took a Shocking Turn--And It Starts With 8-Year-Olds (GuruFocus.com)
09:00AM	Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock (Zacks)
Dec-01-25 12:01PM	Are GLP-1s The New Performance-Enhancing Drug For Careers? (Benzinga)
10:14AM	Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound (Bloomberg)
10:04AM	Eli Lilly cuts cash price for Zepbound weight loss drug vials (Quartz)
09:26AM	VKTX Stock Rises 34% in Three Months: Here's What You Should Know (Zacks)

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsvaerd, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Nordisk A/S	10% Owner	May 30 '25	Proposed Sale	2.14	921,897	1,972,859		May 30 08:31 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NVO

Novo Nordisk ADR

Upgrade your FINVIZ experience